ABIVAX – 2015 Half-Year Results - €57.7 million raised on Euronext and significant clinical progress on chronic Hepatitis B and HIV/AIDS

• €57.7 million raised, covering the company’s net financial needs through the end of 2017
• Strong acceleration in the company’s clinical development program with the launch in early 2015 of the ABVX203 pivotal trial (Phase IIb/III) to address chronic Hepatitis B, and the first phase IIa study on ABX464 for the treatment of HIV/AIDS
• Pioneering partnerships with Cuban life sciences organizations have been strengthened

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41